Immunovant (IMVT) PT Lowered to $33 at Stifel, 'We are buying'

February 2, 2021 9:36 AM EST
Get Alerts IMVT Hot Sheet
Price: $15.88 --0%

Rating Summary:
    10 Buy, 1 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 9 | Down: 8 | New: 34
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Stifel analyst Derek Archila lowered the price target on Immunovant (NASDAQ: IMVT) to $33.00 (from $54.00) while maintaining a Buy rating.

The analyst comments "We are buying this AMs weakness after IMVT announced it was pausing its clinical trials for IMVT-1401 in thyroid eye disease (TED) and warm autoimmune hemolytic anemia (WAIHA) after observing dose dependent LDL increases in patients from its Ph2 study in TED. Interestingly, increases have only been seen in TED patients, and our review of the literature suggests a few things: (1) it's likely this is TED specific given the biology - see below for details, but we don't think similar LDL increases will be seen in other indications outside TED; and (2) other anti-thyroid therapies used in Graves/TED also see similar increases in LDL, which end up being transient. We think IMVT-1401, in a way, is replicating this mechanism. While we will need to see additional data from the company to confirm, the stock is down -50% in the pre-market and we don't think this program is dead."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change, Hot Comments

Related Entities

Stifel